These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 35247543)

  • 1. Novel Bruton's tyrosine kinase inhibitor remibrutinib: Assessment of drug-drug interaction potential as a perpetrator of cytochrome P450 enzymes and drug transporters and the impact of covalent binding on possible drug interactions.
    Schiller H; Huth F; Schuhler C; Drollmann A; Kaul M; Woessner R; Shah B; Weis W; End P
    Eur J Pharm Sci; 2022 May; 172():106155. PubMed ID: 35247543
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel Bruton's Tyrosine Kinase inhibitor remibrutinib: Drug-drug interaction potential as a victim of CYP3A4 inhibitors based on clinical data and PBPK modeling.
    Huth F; Schiller H; Jin Y; Poller B; Schuhler C; Weis W; Woessner R; Drollmann A; End P
    Clin Transl Sci; 2022 Jan; 15(1):118-129. PubMed ID: 34432364
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vitro investigations into the roles of CYP450 enzymes and drug transporters in the drug interactions of zanubrutinib, a covalent Bruton's tyrosine kinase inhibitor.
    Zhang H; Ou YC; Su D; Wang F; Wang L; Sahasranaman S; Tang Z
    Pharmacol Res Perspect; 2021 Dec; 9(6):e00870. PubMed ID: 34664792
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics and Drug-Drug Interaction of Ocedurenone (KBP-5074) in vitro and in vivo.
    Wang P; Liu J; Tan X; Yang F; McCabe J; Zhang J
    Eur J Drug Metab Pharmacokinet; 2023 Jul; 48(4):397-410. PubMed ID: 37357226
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro and physiologically-based pharmacokinetic based assessment of drug-drug interaction potential of canagliflozin.
    Mamidi RNVS; Dallas S; Sensenhauser C; Lim HK; Scheers E; Verboven P; Cuyckens F; Leclercq L; Evans DC; Kelley MF; Johnson MD; Snoeys J
    Br J Clin Pharmacol; 2017 May; 83(5):1082-1096. PubMed ID: 27862160
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Metabolism and interactions of Ivermectin with human cytochrome P450 enzymes and drug transporters, possible adverse and toxic effects.
    Rendic SP
    Arch Toxicol; 2021 May; 95(5):1535-1546. PubMed ID: 33719007
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Brivanib Exhibits Potential for Pharmacokinetic Drug-Drug Interactions and the Modulation of Multidrug Resistance through the Inhibition of Human ABCG2 Drug Efflux Transporter and CYP450 Biotransformation Enzymes.
    Hofman J; Sorf A; Vagiannis D; Sucha S; Kammerer S; Küpper JH; Chen S; Guo L; Ceckova M; Staud F
    Mol Pharm; 2019 Nov; 16(11):4436-4450. PubMed ID: 31633365
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Remibrutinib (LOU064): A selective potent oral BTK inhibitor with promising clinical safety and pharmacodynamics in a randomized phase I trial.
    Kaul M; End P; Cabanski M; Schuhler C; Jakab A; Kistowska M; Kinhikar A; Maiolica A; Sinn A; Fuhr R; Cenni B
    Clin Transl Sci; 2021 Sep; 14(5):1756-1768. PubMed ID: 33834628
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ribociclib shows potential for pharmacokinetic drug-drug interactions being a substrate of ABCB1 and potent inhibitor of ABCB1, ABCG2 and CYP450 isoforms in vitro.
    Sorf A; Hofman J; Kučera R; Staud F; Ceckova M
    Biochem Pharmacol; 2018 Aug; 154():10-17. PubMed ID: 29673999
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of the Clinical Drug-Drug Interaction Potential of Pritelivir on Transporters and CYP450 Enzymes Using a Cocktail Approach.
    de Vries M; Bonsmann S; Pausch J; Sumner M; Birkmann A; Zimmermann H; Kropeit D
    Clin Pharmacol Drug Dev; 2024 Jul; 13(7):755-769. PubMed ID: 38752475
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro investigations into the roles of drug transporters and metabolizing enzymes in the disposition and drug interactions of dolutegravir, a HIV integrase inhibitor.
    Reese MJ; Savina PM; Generaux GT; Tracey H; Humphreys JE; Kanaoka E; Webster LO; Harmon KA; Clarke JD; Polli JW
    Drug Metab Dispos; 2013 Feb; 41(2):353-61. PubMed ID: 23132334
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interactions of Alectinib with Human ATP-Binding Cassette Drug Efflux Transporters and Cytochrome P450 Biotransformation Enzymes: Effect on Pharmacokinetic Multidrug Resistance.
    Hofman J; Sorf A; Vagiannis D; Sucha S; Novotna E; Kammerer S; Küpper JH; Ceckova M; Staud F
    Drug Metab Dispos; 2019 Jul; 47(7):699-709. PubMed ID: 31068367
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Drug-Drug Interaction Potential of Darolutamide: In Vitro and Clinical Studies.
    Zurth C; Koskinen M; Fricke R; Prien O; Korjamo T; Graudenz K; Denner K; Bairlein M; von Bühler CJ; Wilkinson G; Gieschen H
    Eur J Drug Metab Pharmacokinet; 2019 Dec; 44(6):747-759. PubMed ID: 31571146
    [TBL] [Abstract][Full Text] [Related]  

  • 14. P-Glycoprotein (MDR1/ABCB1) Restricts Brain Penetration of the Bruton's Tyrosine Kinase Inhibitor Ibrutinib, While Cytochrome P450-3A (CYP3A) Limits Its Oral Bioavailability.
    van Hoppe S; Rood JJM; Buil L; Wagenaar E; Sparidans RW; Beijnen JH; Schinkel AH
    Mol Pharm; 2018 Nov; 15(11):5124-5134. PubMed ID: 30247919
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vitro evaluation of potential drug interactions mediated by cytochrome P450 and transporters for luseogliflozin, an SGLT2 inhibitor.
    Chino Y; Hasegawa M; Fukasawa Y; Mano Y; Bando K; Miyata A; Nakai Y; Endo H; Yamaguchi JI
    Xenobiotica; 2017 Apr; 47(4):314-323. PubMed ID: 27324291
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In Vitro Investigations into the Potential Drug Interactions of Pseudoginsenoside DQ Mediated by Cytochrome P450 and Human Drug Transporters.
    Li Z; Wang C; Liu J; Li P; Feng H
    Molecules; 2024 May; 29(11):. PubMed ID: 38893358
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interaction potential of the endothelin-A receptor antagonist atrasentan with drug transporters and drug-metabolising enzymes assessed in vitro.
    Weiss J; Haefeli WE
    Cancer Chemother Pharmacol; 2011 Oct; 68(4):1093-8. PubMed ID: 21805352
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification and Characterization of ACP-5862, the Major Circulating Active Metabolite of Acalabrutinib: Both Are Potent and Selective Covalent Bruton Tyrosine Kinase Inhibitors .
    Podoll T; Pearson PG; Kaptein A; Evarts J; de Bruin G; Emmelot-van Hoek M; de Jong A; van Lith B; Sun H; Byard S; Fretland A; Hoogenboom N; Barf T; Slatter JG
    J Pharmacol Exp Ther; 2023 Jan; 384(1):173-186. PubMed ID: 36310034
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rhinacanthin-C Mediated Herb-Drug Interactions with Drug Transporters and Phase I Drug-Metabolizing Enzymes.
    Dunkoksung W; Vardhanabhuti N; Siripong P; Jianmongkol S
    Drug Metab Dispos; 2019 Oct; 47(10):1040-1049. PubMed ID: 31399508
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Remibrutinib (LOU064) inhibits neuroinflammation driven by B cells and myeloid cells in preclinical models of multiple sclerosis.
    Nuesslein-Hildesheim B; Ferrero E; Schmid C; Huck C; Smith P; Tisserand S; Rubert J; Bornancin F; Eichlisberger D; Cenni B
    J Neuroinflammation; 2023 Aug; 20(1):194. PubMed ID: 37633912
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.